BioAdvance News Portfolio News Venatorx Pharmaceuticals

VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

By WebmasterSeptember 25, 2018November 1st, 2024No Comments

VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
VenatoRx is eligible to receive up to $114 million, including upfront milestone payments, in addition to royalties

See more here

Previous PostRelmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Next PostMebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate

VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRelmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels

Next PostMebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate